EMERYVILLE, Calif., January 31, 2023 –( BUSINESS WIRE )– NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Meeting on Thursday, February 2 at two: 30 p. m. Eastern time. To register for the particular event, visit the Sequire Biotechnology website .
“We closed 2022 with one of our best quarters ever for Avenova ® unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business, ” said Mr. Corridor. “We are excited in order to share an update on our opportunities with investors attending this conference. ”
An archived webcast of the presentation will be available upon the NovaBay website . NovaBay will certainly report 2022 fourth quarter and full year financial results on March 23, 2023.
About Sequire
Sequire is a premier investor intelligence and communications platform where companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. More information is available at srax. com and mysequire. com .
About NovaBay Pharmaceuticals, Incorporation.:
NovaBay Pharmaceuticals, Inc. develops plus sells scientifically created and clinically proven eyecare plus skincare products. NovaBay’s leading product, Avenova ® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and will be also obtainable directly to eyecare consumers through online distribution stations such as Amazon. DERMAdoctor ® offers more than 30 OTC dermatologist-developed skincare items through the DERMAdoctor website, well-known traditional plus digital beauty retailers, and international distributors. NovaBay also manufactures plus sells efficient, yet gentle and non-irritating wound care products. The PhaseOne ® brand is distributed through commercial partners in the U. S. for professional use only, and the NeutroPhase ® brand is usually distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the particular commercial progress and future financial performance of NovaBay Pharmaceuticals, Incorporation. This launch contains forward-looking statements that are based upon management’s present expectations, assumptions, estimates, projections and beliefs. These claims include, but are not limited to, statements regarding our own business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future monetary results. These statements involve known plus unknown risks, uncertainties and other factors that may cause actual results or achievements in order to be materially different plus adverse from those expressed in or even implied by the forward-looking claims. Factors that might cause or contribute to such differences include, but are not limited to, dangers and uncertainties relating in order to the size of the particular potential market for the products, the possibility that will the accessible market with regard to the Company’s products will not be as large as anticipated, the Company’s products may not be able to penetrate one or more targeted markets, and revenues can not become sufficient to meet the particular Company’s cash needs. Other risks relating to NovaBay’s company, including risks that could cause results to differ materially through those projected in the forward-looking statements with this press release, are usually detailed within NovaBay’s latest Form 10-Q/K filings plus Registration Statement on Form S-1 filing with the particular Securities and Exchange Commission, especially under the heading “Risk Factors. ” The particular forward-looking claims in this particular release speak only as of this date, plus NovaBay disclaims any intent or obligation to revise or update publicly any kind of forward-looking statement except because required simply by law.
Socialize and Stay Informed on NovaBay ’ s Progress
Like us upon Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or even email [email protected] com
Avenova. com
DERMAdoctor Purchasing Info
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email [email protected] possuindo
DERMAdoctor. com
View source version upon businesswire. possuindo: https://www.businesswire.com/news/home/20230131005342/en/
Contacts
NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
[email protected] com
Investor Contact
LHA Trader Relations
Jody Cain
310-691-7100
[email protected] com